88 related articles for article (PubMed ID: 36992083)
1. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma.
Li XQ; Yin SQ; Chen L; Tulamaiti A; Xiao SY; Zhang XL; Shi L; Miao XC; Yang Y; Xing X
BMC Cancer; 2024 Jan; 24(1):116. PubMed ID: 38262966
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma.
Yuan H; Liu J; Zhao L; Wu P; Chen G; Chen Q; Shen P; Yang T; Fan S; Xiao B; Jiang K
Front Immunol; 2021; 12():800268. PubMed ID: 34956238
[TBL] [Abstract][Full Text] [Related]
3. Action of m6A-related gene signatures on the prognosis and immune microenvironment of colonic adenocarcinoma.
Shugao H; Yinhang W; Jing Z; Zhanbo Q; Miao D
Heliyon; 2024 Jun; 10(11):e31441. PubMed ID: 38845921
[TBL] [Abstract][Full Text] [Related]
4. Solute carrier family 16 member 1 as a potential prognostic factor for pancreatic ductal adenocarcinoma and its influence on tumor immunity.
Wang M; Liu L; Li X; Jiang W; Xiao J; Hao Q; Wang J; Reddy AV; Talbot A; Ikuta S; Tian D; Ren L
J Gastrointest Oncol; 2024 Apr; 15(2):730-746. PubMed ID: 38756638
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between m6A and coding/non-coding RNA in cancer and detection methods of m6A modification residues.
Meng Q; Schatten H; Zhou Q; Chen J
Aging (Albany NY); 2023 Jul; 15(13):6577-6619. PubMed ID: 37437245
[TBL] [Abstract][Full Text] [Related]
6. The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
Li Y; Chen Z; Peng J; Yuan C; Yan S; Yang N; Li P; Kong B
Oncogene; 2023 Jul; 42(31):2386-2401. PubMed ID: 37391593
[TBL] [Abstract][Full Text] [Related]
7. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential.
Zhu TY; Hong LL; Ling ZQ
Biomark Res; 2023 Jun; 11(1):62. PubMed ID: 37280679
[TBL] [Abstract][Full Text] [Related]
8. Novel insights into the interplay between m6A modification and programmed cell death in cancer.
Chen J; Ye M; Bai J; Hu C; Lu F; Gu D; Yu P; Tang Q
Int J Biol Sci; 2023; 19(6):1748-1763. PubMed ID: 37063421
[TBL] [Abstract][Full Text] [Related]
9. The emerging roles and mechanism of N6-methyladenosine (m
Zhu W; Zhao R; Guan X; Wang X
Front Pharmacol; 2023; 14():1192495. PubMed ID: 37284313
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis.
Peng WX; Liu F; Jiang JH; Yuan H; Zhang Z; Yang L; Mo YY
Genes Dis; 2023 Mar; 10(2):554-567. PubMed ID: 37223505
[TBL] [Abstract][Full Text] [Related]
11. SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Fung NN; Man EPS; Leung MH; You CP; Chan WL; Chan SY; Khoo US
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190199
[TBL] [Abstract][Full Text] [Related]
12. m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis.
Jiang X; Jin Z; Yang Y; Zheng X; Chen S; Wang S; Zhang X; Qu N
Front Oncol; 2023; 13():1162300. PubMed ID: 37152066
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the m
Pan L; She H; Wang K; Xia W; Tang H; Fan Y; Ye J
Sci Rep; 2023 Apr; 13(1):6617. PubMed ID: 37095314
[TBL] [Abstract][Full Text] [Related]
14. Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases.
Song M; Pang L; Zhang M; Qu Y; Laster KV; Dong Z
Signal Transduct Target Ther; 2023 Apr; 8(1):148. PubMed ID: 37029108
[TBL] [Abstract][Full Text] [Related]
15. Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC).
Chen H; Luo W; Lu X; Zhang T
Heliyon; 2023 Nov; 9(11):e20969. PubMed ID: 37928039
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation.
Wang K; Wang X; Pan Q; Zhao B
Mol Cancer; 2023 Oct; 22(1):167. PubMed ID: 37803304
[TBL] [Abstract][Full Text] [Related]
17. M6A-Related Long Non-Coding RNA Displays Utility in Predicting Prognosis, Portraying the Tumor Immune Microenvironment and Guiding Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Xu G; Ji Y; Wang L; Xu H; Shen C; Ye H; Yang X
Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992083
[TBL] [Abstract][Full Text] [Related]
18. Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma.
Wang Y; Ji Y; Xu Q; Huang W
Front Genet; 2022; 13():866340. PubMed ID: 36226185
[No Abstract] [Full Text] [Related]
19. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
